BPC-157 vs ARA-290 (2026): Tissue-Repair Peptides in Inflammation and Nerve-Injury Research
BPC-157 vs ARA-290: one recruiting Phase 2 trial vs three completed Phase 2 studies. Compare mechanisms, evidence and 503A status of two tissue-repair peptides.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
BPC-157 vs ARA-290 is a comparison between two tissue-repair peptides that sit at very different points on the evidence ladder: BPC-157 has a large preclinical record and one registered Phase 2 trial that is still recruiting, while ARA-290 (cibinetide) has already completed randomized, placebo-controlled Phase 2 studies in small-fiber neuropathy.
Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.
Quick Answer: BPC-157 is a 15-amino-acid gastric peptide studied mainly in rodent tendon, muscle and gut-injury models, with human data limited to pilot studies and the recruiting Phase 2 trial NCT07437547. ARA-290 is an 11-amino-acid erythropoietin-derived peptide that activates the innate repair receptor and has completed Phase 2 trials reporting improved neuropathic symptoms and corneal nerve fiber measures.
TL;DR:
- BPC-157 acts on angiogenesis, nitric oxide signalling and fibroblast activity; ARA-290 selectively activates the EPO receptor/CD131 innate repair receptor without stimulating red-cell production.
- BPC-157 evidence is overwhelmingly preclinical; ARA-290 has randomized Phase 2 data in sarcoidosis and type 2 diabetes neuropathy.
- The FDA PCAC voted 8-6 in July 2026 to recommend BPC-157 for the 503A Bulks List; ARA-290 was not on that docket.
- Neither compound is FDA-approved, and BPC-157 is named on the WADA Prohibited List.
- Researchers select BPC-157 for musculoskeletal and GI injury models and ARA-290 for neuropathy and innate-immune inflammation models.
| Parameter | BPC-157 | ARA-290 (cibinetide) |
|---|---|---|
| Highest trial phase | Phase 2 (NCT07437547, recruiting) | Phase 2b (completed) |
| Key human endpoint | Return to sport, MRI injury volume (results expected 2027–2028) | Corneal nerve fiber area +697 μm² vs placebo at day 28 (4 mg) |
| Dosing interval in trials | Once daily subcutaneous, 14 days | Once daily subcutaneous, 28 days |
| Developer / sponsor | Hudson Biotech (trial sponsor) | Araim Pharmaceuticals |
| Length | 15 amino acids | 11 amino acids |
BPC-157: Mechanism and evidence base
BPC-157 (Body Protective Compound-157) is a synthetic pentadecapeptide derived from a protein sequence found in human gastric juice. Its molecular formula is C62H98N16O22 with a molecular weight of roughly 1,419 g/mol. A 2026 review in the International Journal of Molecular Sciences (PMID 41898733) summarizes the mechanism literature: preclinical studies report that BPC-157 "supports angiogenesis, collagen synthesis, fibroblast activity, and modulation of nitric oxide pathways," with downstream effects on healing of "muscle, tendon, ligament, bone, and gastrointestinal tissue."
The same review describes reduced inflammatory cytokine activity (IL-6 and TNF-α in injury models), improved microvascular integrity, and pain-modulating effects attributed to peripheral and dopaminergic mechanisms. Most of this work comes from rat models of tendon transection, muscle crush, gastric lesions and anastomosis healing, with a large share originating from a single research group in Zagreb. That concentration of authorship is one of the most frequently cited limitations in critical reviews.
Human evidence remains thin. The 2026 review notes that human research "remains limited to small pilot studies investigating musculoskeletal pain, interstitial cystitis, and intravenous administration." The first registered randomized controlled trial, NCT07437547 (BPC-HAMSTR), began in February 2026. It randomizes 120 participants with MRI-confirmed grade II hamstring strain 1:1 to subcutaneous BPC-157 or placebo once daily for 14 days, alongside standardized rehabilitation. Co-primary endpoints are time to return to unrestricted sport and change in MRI-assessed injury volume at day 14. Primary completion is estimated for February 2027. Our NCT07437547 trial analysis covers the protocol in detail.
ARA-290: Mechanism and evidence base
ARA-290, also known by its INN cibinetide, is an 11-amino-acid peptide engineered from the helix B surface of erythropoietin (EPO). Its molecular formula is C56H86N16O18 (about 1,295 g/mol). The design rationale is selectivity: classical EPO signals through an EPO receptor homodimer to drive red-cell production, while ARA-290 targets a heteromeric complex of the EPO receptor and the beta common receptor (CD131), described as the innate repair receptor. Activation of this receptor in preclinical models is associated with reduced inflammatory signalling and tissue-protective effects, without the erythropoietic and thrombotic liabilities of EPO itself.
The clinical program has focused on small-fiber neuropathy. In a blinded, placebo-controlled trial in sarcoidosis-associated small nerve fiber loss (PMID 24136731, Molecular Medicine, 2013), 28 days of daily subcutaneous ARA-290 significantly improved neuropathic symptom scores and was associated with increased corneal small nerve fiber density, changes in cutaneous temperature sensitivity and a longer 6-minute walk distance.
A second Phase 2 study in type 2 diabetes (PMID 25387363, Molecular Medicine, 2014) reported improvement in hemoglobin A1c and lipid profiles across a 56-day observation period, significant improvement in PainDetect neuropathic scores, and increased corneal nerve fiber density in participants who started with low baseline values. A larger Phase 2b trial in 64 subjects with sarcoid-associated neuropathy (PMID 28475703, Investigative Ophthalmology & Visual Science, 2017) reported a placebo-corrected increase in corneal nerve fiber area of 697 μm² in the 4 mg arm at day 28 (P = 0.012).
Side-by-side comparison
| Feature | BPC-157 | ARA-290 |
|---|---|---|
| Origin | Fragment of a gastric juice protein | Engineered from EPO helix B |
| Primary target | No single receptor identified; NO, VEGFR2, FAK-paxillin and growth hormone receptor pathways reported | Innate repair receptor (EPOR/CD131 heterocomplex) |
| Plasma half-life | Short (minutes) in rodent pharmacokinetic studies | Short (minutes); tissue effects persist beyond plasma exposure |
| Routes studied | Oral, intraperitoneal, subcutaneous, topical, intravenous | Subcutaneous, intravenous |
| Main research models | Tendon, ligament, muscle, bone and GI injury | Small-fiber neuropathy, metabolic inflammation, ischemic injury |
| Human evidence | Pilot studies; Phase 2 recruiting | Multiple completed Phase 2 RCTs |
| Erythropoietic activity | Not applicable | None reported (by design) |
The half-life comparison is useful for planning, and the half-life chart puts both compounds next to other tissue-repair peptides. Both peptides are cleared quickly from plasma, so effects reported in longer studies are generally attributed to downstream signalling rather than sustained exposure.
Differential research applications
The two compounds rarely compete for the same study design. BPC-157 is the reference compound when the research question involves structural repair of connective tissue or the gastrointestinal mucosa. Its oral stability in gastric juice, reported repeatedly in rodent work, has also made it a model compound for studying orally administered peptides in GI injury, an application that sets it apart from most other repair peptides, including TB-500.
ARA-290 is the more common choice when the endpoint is neurological or immunological. Corneal confocal microscopy, intraepidermal nerve fiber density and validated neuropathic pain questionnaires are established readouts in its trials (PMID 24136731; PMID 28475703), which gives investigators a translational bridge from animal models to human surrogate endpoints. Its EPO lineage also makes it relevant to research separating tissue-protective from hematopoietic EPO signalling.
Researchers building multi-compound repair studies often add a third arm with a copper peptide such as GHK-Cu, which works through extracellular-matrix gene expression rather than either pathway above. The evidence explorer lets researchers filter the published record by study type to see how far apart these evidence bases are. For trial monitoring, the trial tracker follows NCT07437547 and other registered peptide studies.
Regulatory and compounding status
| Status | BPC-157 | ARA-290 |
|---|---|---|
| FDA approval | None | None (investigational) |
| 503A status | Category 2; PCAC voted 8-6 (1 abstention) on July 23, 2026 to recommend Bulks List placement, pending FDA rulemaking | Not on the July 2026 PCAC docket |
| EMA | Not authorized | Not authorized |
| WADA | Named under S0 (non-approved substances) | Not named; S0 catch-all applies to unapproved substances |
The PCAC recommendation for BPC-157 is not binding. Compounding pharmacies still cannot prepare BPC-157 from bulk under Section 503A until the FDA completes notice-and-comment rulemaking; the PCAC tracker follows each step. ARA-290 has followed a conventional drug-development route through sponsor-led clinical trials rather than the compounding pathway.
Cited studies
- PMID 41898733, "From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management" (International Journal of Molecular Sciences, 2026). https://doi.org/10.3390/ijms27062876
- PMID 24136731: "ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Increases Corneal Nerve Fiber Density" (Molecular Medicine, 2013). https://doi.org/10.2119/molmed.2013.00122
- PMID 25387363: "ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes" (Molecular Medicine, 2014). https://doi.org/10.2119/molmed.2014.00215
- PMID 28475703: "Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain" (Investigative Ophthalmology & Visual Science, 2017). https://doi.org/10.1167/iovs.16-21291
- ClinicalTrials.gov NCT07437547, "BPC 157 for Acute Hamstring Muscle Strain Repair." https://clinicaltrials.gov/study/NCT07437547
Frequently asked questions
Q: What is the difference between BPC-157 and ARA-290?
A: BPC-157 is a gastric-derived pentadecapeptide studied mainly for connective-tissue and GI repair in animal models. ARA-290 is an erythropoietin-derived peptide that activates the innate repair receptor and has been studied mainly in neuropathy. Their mechanisms and evidence bases do not overlap much.
Q: Has ARA-290 been tested in humans?
A: Yes. Randomized, placebo-controlled Phase 2 trials in sarcoidosis-associated small-fiber neuropathy and type 2 diabetes reported improved neuropathic symptom scores and corneal nerve fiber measures (PMID 24136731; PMID 25387363; PMID 28475703). It remains investigational and is not approved in any jurisdiction.
Q: Is there a clinical trial for BPC-157?
A: NCT07437547 is a randomized, double-blind Phase 2 trial in 120 participants with grade II hamstring strain that began recruiting in February 2026. Primary completion is estimated for February 2027, so results are not yet available.
Q: Is ARA-290 the same as erythropoietin?
A: No. ARA-290 is an 11-amino-acid fragment engineered from erythropoietin's helix B. It was designed to bind the innate repair receptor and does not activate the receptor homodimer that drives red-cell production, so no erythropoietic effect has been reported in published studies.
Q: Are BPC-157 and ARA-290 legal to compound?
A: Neither is FDA-approved. BPC-157 remains in 503A Category 2 despite a favorable July 2026 PCAC vote, pending FDA rulemaking, and ARA-290 has not been reviewed for the 503A Bulks List. BPC-157 is also named on the WADA Prohibited List.
See also:
- ARA-290 and Erythropoietin-Derived Peptides: deeper background on the innate repair receptor and EPO-derived peptide research
- TB-500 vs BPC-157 Comparison: how BPC-157 compares with the other most-studied tissue-repair peptide
- BPC-157 Phase 2 Hamstring Trial (NCT07437547): protocol details for the first registered BPC-157 RCT
For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.